General information Lecanemab is one of the first Alzheimer’s treatments designed to remove amyloid protein in the brain, and has been approved by the FDA for treatment of patients with “mild cognitive impairment” and mild dementia stages of Alzheimer’s disease. Generic name: lecanemab Brand name: Leqembi TM Made by: Eisai and Biogen What is it proven to do? Remove beta amyloid protein from the brain, which is one of the Alzheimer’s proteins. Slow the worsening of Alzheimer’s disease to a modest degree (27% over 18 months), based on the cognitive and functional test, Clinical Dementia Rating